Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1997 2
1998 1
1999 1
2000 4
2001 3
2002 4
2003 4
2004 8
2005 6
2006 10
2007 18
2008 10
2009 11
2010 8
2011 11
2012 11
2013 7
2014 8
2015 14
2016 21
2017 22
2018 28
2019 37
2020 26
2021 37
2022 42
2023 49
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
PURPOSE: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediat …
PURPOSE: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly …
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. Owen DH, et al. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. J Hematol Oncol. 2019. PMID: 31215500 Free PMC article. Review.
Treatment options for recurrent or refractory disease are limited, and the treatments that do exist are associated with significant treatment-related toxicities. Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in SCLC and other neuroendocr …
Treatment options for recurrent or refractory disease are limited, and the treatments that do exist are associated with significant treatmen …
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. Jaspers JE, et al. J Clin Invest. 2023 May 1;133(9):e166028. doi: 10.1172/JCI166028. J Clin Invest. 2023. PMID: 36951942 Free PMC article.
In this study, we developed a chimeric antigen receptor (CAR) against DLL3 that displays antitumor efficacy in xenograft and murine SCLC models. ...All together, these results define DLL3-targeting CAR T cells that produce IL-18 as a potentially promising novel stra …
In this study, we developed a chimeric antigen receptor (CAR) against DLL3 that displays antitumor efficacy in xenograft and murine S …
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. Yao J, et al. Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161. Oncologist. 2022. PMID: 35983951 Free PMC article. Review.
METHODS: This article is a narrative review that highlights the role of DLL3 in NEN progression and prognosis, the potential for therapeutic targeting of DLL3, and ongoing studies of DLL3-targeting therapies. ...DLL3 is expressed on the cell surface of …
METHODS: This article is a narrative review that highlights the role of DLL3 in NEN progression and prognosis, the potential for ther …
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, Bailis JM, Bebb G, Goldrick A, Umejiego J, Paz-Ares L. Rudin CM, et al. J Hematol Oncol. 2023 Jun 24;16(1):66. doi: 10.1186/s13045-023-01464-y. J Hematol Oncol. 2023. PMID: 37355629 Free PMC article. Review.
Several DLL3-targeted therapies are being developed for the treatment of SCLC and other neuroendocrine carcinomas, including antibody-drug conjugates (ADCs), T-cell engager (TCE) molecules, and chimeric antigen receptor (CAR) therapies. ...We conclude with a discussion of …
Several DLL3-targeted therapies are being developed for the treatment of SCLC and other neuroendocrine carcinomas, including antibody …
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Chou J, et al. Cancer Res. 2023 Jan 18;83(2):301-315. doi: 10.1158/0008-5472.CAN-22-1433. Cancer Res. 2023. PMID: 36351060 Free PMC article.
Late relapsing tumors after AMG 757 treatment exhibited lower DLL3 levels, suggesting antigen loss as a resistance mechanism, particularly in tumors with heterogeneous DLL3 expression. ...SIGNIFICANCE: The preclinical and clinical evaluation of DLL3-directed …
Late relapsing tumors after AMG 757 treatment exhibited lower DLL3 levels, suggesting antigen loss as a resistance mechanism, particu …
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ. Saunders LR, et al. Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. Sci Transl Med. 2015. PMID: 26311731 Free PMC article.
DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjugate (ADC), SC16LD6.5, comprised of a humanized anti-DLL3 monoclonal antibody conjugated to a DNA-damaging pyrrolobenzodiazepine (PBD) …
DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjuga …
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F, Homann O, Friedrich M, Pearson JT, Raum T, Yang Y, Caenepeel S, Stevens J, Beltran PJ, Canon J, Coxon A, Bailis JM, Hughes PE. Giffin MJ, et al. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17. Clin Cancer Res. 2021. PMID: 33203642
We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3)-a target that is selectively expressed in SCLC tumors, but with minimal normal tissue expression. ...CONCLUSIONS: AMG 757 has a c …
We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 ( …
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.
Cortinovis DL, Colonese F, Abbate MI, Sala L, Meazza Prina M, Cordani N, Sala E, Canova S. Cortinovis DL, et al. Front Med (Lausanne). 2022 Dec 1;9:989405. doi: 10.3389/fmed.2022.989405. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36530878 Free PMC article. Review.
In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC....
In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failur …
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S, Voynov V, Drobits-Handl B, Giragossian C, Trapani F, Nixon AE, Scheer JM, Adam PJ. Hipp S, et al. Clin Cancer Res. 2020 Oct 1;26(19):5258-5268. doi: 10.1158/1078-0432.CCR-20-0926. Epub 2020 Jun 18. Clin Cancer Res. 2020. PMID: 32554516
RESULTS: Selective binding of DLL3/CD3 ITE to DLL3-positive tumor cells and T-cells induces formation of an immunological synapse resulting in tumor cell lysis and activation of T-cells. ...These data support clinical testing of the DLL3/CD3 ITE in patients w …
RESULTS: Selective binding of DLL3/CD3 ITE to DLL3-positive tumor cells and T-cells induces formation of an immunological syna …
380 results